Merck KGaA Insights
Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.
A sample of Merck KGaA Insights data
| Headline | Published | Journalists |
|---|---|---|
| Deserunt mollit sunt Lorem laborum do id aliqua dolore | 22 Jul 2022 | Lorem |
| Neglected Tropical Diseases: Non-Profits Lead the Way as Private Sectors Lags | 30 Jun 2022 | Adam Zamecnik |
| LoA Update: Merck KGaA’s Berzosertib Advancement Prospects Dip in Small-Cell Lung Cancer, Solid Tumors After Phase II Discontinuation | 10 Jun 2022 | Urte Fultinaviciute |
| LoA Update: Merck’s schistosomiasis asset levo-praziquantel sees its Likelihood of Approval rise after positive Phase III results | 26 Nov 2021 | Adam Zamecnik |
Feature
Delivers exclusive investigative journalist content including breaking news and analysis ahead of market-moving events.
Benefit
Drug Insights:
- Forward-looking, nuanced, qualitative asset analysis on development, approval & market/reimbursement potential
- Material intelligence on competitors, including breaking news
- Insight on companies’ business development needs and strategies
Outsourcing Insights:
Insight on companies’ CRO and business development needs, strategies and relationships
Value
Remove risk and uncertainty
Gain a competitive edge
Secure actionable leads
Premium databases is part of our industry range of products
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer